The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Targets high-growth eye care expansion push
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The investment will support the company’s plans to expand its network of specialised surgical hospitals across India.
The company allocated €56 million to research and development for next-generation line solutions
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
Subscribe To Our Newsletter & Stay Updated
